Xhale Issued U.S. Patent for Non-invasive Monitoring of Blood Glucose Using Exhaled Breath

Share Article

Xhale, Inc. announced today the issuance of U.S. patent 7,914,460, disclosing a system and method for non-invasive monitoring of glucose concentrations in blood through the analysis of exhaled breath condensate.

News Image

Xhale, Inc. announced today the issuance of U.S. patent 7,914,460, disclosing a system and method for noninvasive monitoring of glucose concentrations in blood through the analysis of exhaled breath condensate. Such a system, when successfully commercialized and approved, would allow noninvasive blood glucose monitoring via the breath, using a small handheld device to accurately and conveniently measure blood glucose levels by simply exhaling into the device.

According to the U.S. Centers for Disease Control, diabetes affects more than 25 million Americans and is the seventh leading cause of death in the United States. Regularly checking blood glucose levels is one of the most important steps that patients with diabetes can take to successfully manage diabetes and prevent the significant complications of this devastating disease, including kidney failure, amputations, blindness, heart disease, stroke and death.

The most widely used devices to monitor blood glucose levels rely on blood samples that are obtained from the finger or other body site using a small needle. The pain, discomfort and inconvenience of obtaining and testing blood samples using these devices prevent many patients with diabetes from measuring blood glucose levels as often as recommended and as often as needed to successfully manage their health. The availability of a breath-based glucose meter could increase the frequency of blood glucose monitoring, with the potential to positively impact the lives of patients with diabetes by making it easier and more convenient for them to successfully monitor their blood glucose and manage their diabetes.

According to Richard Melker, M.D. Ph.D, Chief Technology Officer and co-founder of Xhale, “The great value of this technology lies in its ability to provide important information to patients and healthcare providers that can be used to make better healthcare decisions, reduce healthcare costs, and improve health outcomes. We hope that continued research will result in this breakthrough technology being available to patients, caregivers, healthcare providers and payers, all of whom would benefit from a more user-friendly glucose monitor.”

Additional research and development will be required to bring this innovation to patients who need it. Xhale, a research-driven medical device company, is a world leader in the use of sensors that analyze vapor and exhaled breath. The company, established in 2005, is dedicated to improving lives through innovation and technology, creating solutions that address unmet medical needs and advancing novel technologies for personalized medicine, point-of-need health monitoring, and diagnostics. Xhale is developing cost-effective, noninvasive technologies that provide critical information in real time about patient care and medication use. Xhale currently has 12 issued U.S. and European patents and 70 U.S. and foreign equivalent patent applications.

For more information, please visit http://www.xhale.com or contact Stephanie Warrington, Vice President of Corporate Affairs and Development, at 352.371.8488.

1 http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Stephanie Warrington, Vice President
Xhale, Inc.
(352) 371-8488
Email >
Visit website